181 related articles for article (PubMed ID: 24687402)
21. The association of hepcidin, reticulocyte hemoglobin equivalent and anemia-related indicators on anemia in chronic kidney disease.
Gao Z; Hu Y; Gao Y; Ma X; Hu Z
Medicine (Baltimore); 2023 Apr; 102(17):e33558. PubMed ID: 37115087
[TBL] [Abstract][Full Text] [Related]
22. Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents.
Tessitore N; Girelli D; Campostrini N; Bedogna V; Pietro Solero G; Castagna A; Melilli E; Mantovani W; De Matteis G; Olivieri O; Poli A; Lupo A
Nephrol Dial Transplant; 2010 Dec; 25(12):3996-4002. PubMed ID: 20538788
[TBL] [Abstract][Full Text] [Related]
23. Hepcidin is a key mediator of anemia of inflammation in Crohn's disease.
Basseri RJ; Nemeth E; Vassilaki ME; Basseri B; Enayati P; Shaye O; Bourikas LA; Ganz T; Papadakis KA
J Crohns Colitis; 2013 Sep; 7(8):e286-91. PubMed ID: 23219355
[TBL] [Abstract][Full Text] [Related]
24. The relation of hepcidin to iron disorders, inflammation and hemoglobin in chronic kidney disease.
Mercadal L; Metzger M; Haymann JP; Thervet E; Boffa JJ; Flamant M; Vrtovsnik F; Houillier P; Froissart M; Stengel B;
PLoS One; 2014; 9(6):e99781. PubMed ID: 24978810
[TBL] [Abstract][Full Text] [Related]
25. Significance of Content of the Reticulocyte Hemoglobin in the Management of Renal Anemia.
Ogawa C; Tsuchiya K; Nitta K; Maeda K
Blood Purif; 2019; 47 Suppl 2():70-73. PubMed ID: 30943480
[TBL] [Abstract][Full Text] [Related]
26. Oral Iron Treatment Response and Predictors in Anaemic Adolescents and Adults with IBD: A Prospective Controlled Open-Label Trial.
Rampton DS; Goodhand JR; Joshi NM; Karim AB; Koodun Y; Barakat FM; Macken L; Ward DG; Iqbal TH; Epstein J; Fell JM; Sanderson IR
J Crohns Colitis; 2017 Jun; 11(6):706-715. PubMed ID: 27932449
[TBL] [Abstract][Full Text] [Related]
27. Serum hepcidin-25 levels and anemia in non-dialysis chronic kidney disease patients: a cross-sectional study.
Uehata T; Tomosugi N; Shoji T; Sakaguchi Y; Suzuki A; Kaneko T; Okada N; Yamamoto R; Nagasawa Y; Kato K; Isaka Y; Rakugi H; Tsubakihara Y
Nephrol Dial Transplant; 2012 Mar; 27(3):1076-83. PubMed ID: 21799206
[TBL] [Abstract][Full Text] [Related]
28. Assessing iron status: beyond serum ferritin and transferrin saturation.
Wish JB
Clin J Am Soc Nephrol; 2006 Sep; 1 Suppl 1():S4-8. PubMed ID: 17699374
[TBL] [Abstract][Full Text] [Related]
29. Hepcidin and proinflammatory markers in children with chronic kidney disease: A case-control study
.
Goyal KK; Saha A; Sahi PK; Kaur M; Dubey NK; Goyal P; Upadhayay AD
Clin Nephrol; 2018 May; 89(5):363-370. PubMed ID: 29451472
[TBL] [Abstract][Full Text] [Related]
30. Hepcidin and regulation of iron homeostasis in maintenance hemodialysis patients.
Sany D; Elsawy AE; Elshahawy Y
Saudi J Kidney Dis Transpl; 2014 Sep; 25(5):967-73. PubMed ID: 25193892
[TBL] [Abstract][Full Text] [Related]
31. Dilemma: Correlation Between Serum Level of Hepcidin and IL-6 in Anemic Myeloma Patients.
Ibricevic-Balic L; Icindic-Nakas E; Hasic S; Kiseljakovic E; Sofo-Hafizovic A; Balic S
Med Arch; 2016 Dec; 70(6):429-432. PubMed ID: 28210014
[TBL] [Abstract][Full Text] [Related]
32. Hepcidin and GDF-15 are potential biomarkers of iron deficiency anaemia in chronic kidney disease patients in South Africa.
Nalado AM; Olorunfemi G; Dix-Peek T; Dickens C; Khambule L; Snyman T; Paget G; Mahlangu J; Duarte R; George J; Naicker S
BMC Nephrol; 2020 Sep; 21(1):415. PubMed ID: 32993549
[TBL] [Abstract][Full Text] [Related]
33. Hepcidin and iron metabolism disorders in patients with chronic kidney disease.
Jelić M; Cvetković T; Djordjević V; Damnjanovć G; Vlahović P; Kocić G; Djindjić N; Jovović B; Antić A
Vojnosanit Pregl; 2013 Apr; 70(4):368-73. PubMed ID: 23700940
[TBL] [Abstract][Full Text] [Related]
34. Hepcidin resistance in dysmetabolic iron overload.
Rametta R; Dongiovanni P; Pelusi S; Francione P; Iuculano F; Borroni V; Fatta E; Castagna A; Girelli D; Fargion S; Valenti L
Liver Int; 2016 Oct; 36(10):1540-8. PubMed ID: 26998752
[TBL] [Abstract][Full Text] [Related]
35. Effect of atorvastatin on iron metabolism regulation in patients with chronic kidney disease - a randomized double blind crossover study.
Masajtis-Zagajewska A; Nowicki M
Ren Fail; 2018 Nov; 40(1):700-709. PubMed ID: 30741616
[TBL] [Abstract][Full Text] [Related]
36. Serum hepcidin concentrations correlate with ferritin in patients with inflammatory bowel disease.
Mecklenburg I; Reznik D; Fasler-Kan E; Drewe J; Beglinger C; Hruz P;
J Crohns Colitis; 2014 Nov; 8(11):1392-7. PubMed ID: 24825446
[TBL] [Abstract][Full Text] [Related]
37. Role of C-reactive protein, reticulocyte haemoglobin content and inflammatory markers in iron and erythropoietin administration in dialysis patients.
El-Khatib M; Duncan HJ; Kant KS
Nephrology (Carlton); 2006 Oct; 11(5):400-4. PubMed ID: 17014552
[TBL] [Abstract][Full Text] [Related]
38. Systemic inflammation up-regulates serum hepcidin in exacerbations and stabile chronic obstructive pulmonary disease.
Tandara L; Grubisic TZ; Ivan G; Jurisic Z; Tandara M; Gugo K; Mladinov S; Salamunic I
Clin Biochem; 2015 Dec; 48(18):1252-7. PubMed ID: 26164540
[TBL] [Abstract][Full Text] [Related]
39. Hepcidin and risk of anemia in CKD: a cross-sectional and longitudinal analysis in the CKiD cohort.
Atkinson MA; Kim JY; Roy CN; Warady BA; White CT; Furth SL
Pediatr Nephrol; 2015 Apr; 30(4):635-43. PubMed ID: 25380788
[TBL] [Abstract][Full Text] [Related]
40. Hepcidin-25 in chronic hemodialysis patients is related to residual kidney function and not to treatment with erythropoiesis stimulating agents.
van der Weerd NC; Grooteman MP; Bots ML; van den Dorpel MA; den Hoedt CH; Mazairac AH; Nubé MJ; Penne EL; Gaillard CA; Wetzels JF; Wiegerinck ET; Swinkels DW; Blankestijn PJ; Ter Wee PM;
PLoS One; 2012; 7(7):e39783. PubMed ID: 22808058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
